EMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Read ArticleLinks:
Links:
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Read ArticleDr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read ArticleDr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read ArticleJanus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the indications for these medical
Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.
2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians. While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list
Read ArticleDr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com
Read ArticleA prospective study of patients with limited cutaneous lupus erythematosus shows that early introduction of hydroxychloroquine may prevent progression to systemic lupus erythematosus.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!
Read ArticleScience and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct
Read ArticleA post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI. Adalimumab was equally effective in patients
Read ArticleBMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter Clinical Dermatology Conference in Hawaii
Dr. John Cush @RheumNow( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read ArticleThe always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
Read ArticleWith their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
Read Post